main-image-costim

CoStim Pharmaceuticals

CoStim Pharmaceuticals is developing novel antibodies targeting immune checkpoint inhibitors for oncology indications. The company was acquired in February 2014 by Novartis (NYSE: NVS).

Headquarters Cambridge, MA
Pipeline Preclinical at the time of acquisition